Gain Therapeutics reports 12-month Parkinson's data for rexaceract; Phase 2 planned Q1 2027
Gain Therapeutics said a poster on long-term open-label extension data for rexaceract in Parkinson's disease will be presented at the International Congress of Parkinson's Disease and Movement Disorders in Seoul, October 4-8, 2026. The company reported that MDS-UPDRS motor scores were stable over 12 months in 12 evaluable participants and that preliminary data show the drug is generally well tolerated, and it expects to submit a new Phase 2 protocol to the FDA in the coming weeks.
Key points
- Poster to be presented at the Congress in Seoul, Korea, October 4-8, 2026
- 12 of 13 evaluable patients completed 12 months of dosing as of August 31, 2026; one more is scheduled to finish in November 2026
- MDS-UPDRS motor scores stable over 12 months in the 12 evaluable participants, with no clinically meaningful progression
- Company expects to start the Phase 2 trial in Parkinson's disease in the first quarter of 2027
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.